Neovasc (NASDAQ:NVCN) & Accelerate Diagnostics (AXDX) Financial Review

Neovasc (NASDAQ: NVCN) and Accelerate Diagnostics (NASDAQ:AXDX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.


This table compares Neovasc and Accelerate Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neovasc -928.66% -25.08% 11.97%
Accelerate Diagnostics -5,062.48% -67.44% -63.75%

Institutional & Insider Ownership

19.3% of Neovasc shares are owned by institutional investors. Comparatively, 38.5% of Accelerate Diagnostics shares are owned by institutional investors. 51.4% of Accelerate Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for Neovasc and Accelerate Diagnostics, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neovasc 0 0 3 0 3.00
Accelerate Diagnostics 0 0 2 0 3.00

Neovasc currently has a consensus target price of $6.33, indicating a potential upside of 486.42%. Accelerate Diagnostics has a consensus target price of $33.00, indicating a potential upside of 54.93%. Given Neovasc’s higher possible upside, research analysts clearly believe Neovasc is more favorable than Accelerate Diagnostics.

Volatility & Risk

Neovasc has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500. Comparatively, Accelerate Diagnostics has a beta of 1.95, meaning that its stock price is 95% more volatile than the S&P 500.

Earnings & Valuation

This table compares Neovasc and Accelerate Diagnostics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Neovasc $8.99 million 9.48 -$24.55 million ($1.32) -0.82
Accelerate Diagnostics $1.29 million 859.17 -$61.92 million ($1.23) -17.32

Neovasc has higher revenue and earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Neovasc, indicating that it is currently the more affordable of the two stocks.


Neovasc beats Accelerate Diagnostics on 7 of the 12 factors compared between the two stocks.

About Neovasc

Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.

What are top analysts saying about Neovasc Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Neovasc Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit